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During the past few years, biomarkers have emerged as an indispensible tool in the diagnosis of pneumonia. To ﬁnd an ideal
diagnostic biomarker for pneumonia is not an easy task. Not only should it allow an early diagnosis of the condition, but it should
also allow diﬀerential diagnosis from other noninfectious conditions. Ongoing research is being done in this ﬁeld so as to put an
array of biomarkers at the disposal of doctors to improve the diagnosis of pneumonia when patients present to them with cough or
nonspeciﬁc symptoms which could easily be misinterpreted as symptoms of other conditions. Procalcitonin and soluble triggering
receptor expressed on myeloid cells-1 have emerged as reliable diagnostic markers in pneumonia, and are better when compared
to other markers, namely, C-reactive protein, leukocyte count, and proinﬂammatory cytokines. Many other biomarkers are being
studied for their probable use in diagnosing pneumonia but have yet to prove their beneﬁt.
Copyright © 2009 H. Summah and J.-M. Qu. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Pneumonia has a high morbidity and mortality rate all
around the world today [1]. Very often, clinical signs of
pneumonia can be very elusive. At the heart of the dilemma,
the question remains: “what is the fastest way to come to
the correct diagnosis?” Because the faster the diagnosis is
reached, the earlier the treatment begins. However, there
is almost always a large lapse of time between the time
of onset of symptoms and the start antibiotic therapy due
to delayed diagnosis. In an attempt to achieve the rapid
diagnosis of pneumonia and shortened antibiotic courses,
an innovative approach is now being contemplated—the
use of biomarkers. Till now, there is no universal deﬁnition
of a biomarker, but it can be understood to be any
biomolecule that is associated with a particular pathological
or physiological state. Ideally, a biomarker should be one
which cannot be detected or whose value is very low in
the absence of inﬂammation; it should rise with increasing
inﬂammatory processes and should decrease with resolving
inﬂammation.
Physicians are becoming more and more interested in
the use of biomarkers since there is no “gold standard”
which is both sensitive and speciﬁc enough to help them
reach the “correct” diagnosis. A “correct” diagnosis would be
one in which the causative pathogen can be identiﬁed mor-
phologically. However, 70% of patients with radiologically
conﬁrmed community-acquired pneumonia (CAP) do not
have the causative organism identiﬁed. But to what extent
should we rely on biomarkers to reach our diagnosis? In
their recently published review article, P. Schuetz et al. stated
that “only randomized controlled trials (RCTs), in which
antimicrobial therapy is guided by speciﬁc cut oﬀ ranges
of the biomarkers and in which the primary measure of
eﬃcacyismedicaloutcome,havethepotentialtoevaluatethe
ultimate clinical usefulness of a diagnostic biomarker” [2].
Hence, the growing need of RCTs on biomarkers to evaluate
their use in the diagnosis of pneumonia.
Some of the biomarkers which are at the oﬃng as
an adjunct in the diagnosis of pneumonia include C-
reactive protein, leukocyte count, immunoglobulins, and
proinﬂammatory cytokines. There are other biomarkers
whose importance is growing in the medical ﬁeld. They
are procalcitonin (PCT) and Triggering receptor expressed
on myeloid cells-1 (TREM-1). This paper mainly focuses
on C-reactive protein, procalcitonin, and Soluble Triggering2 Mediators of Inﬂammation
receptor expressed on myeloid cells-1 (TREM-1). There are
some other biomarkers which are still being studied for their
probable use in pneumonia; these include copeptin, cortisol,
endotoxin, proadrenomedullin, amongst others.
2. C-ReactiveProtein(CRP)
C-reactive protein (CRP), identiﬁed in 1930, is an acute-
phase protein. Whenever there is an infection or tissue
inﬂammation, interleukin-6, interleukin-1β,a n dt u m o r
necrosis factor-α stimulate hepatocytes to synthesise CRP.
Within4–6 hoursofstimulation, CRPissecreted.Thereafter,
its level doubles every 8 hours and reaches its maximum
value at 36–50 hours. Once the stimulus is no longer present,
the CRP value starts falling with a half-life of 19 hours [3].
For many years, the value of CRP in healthy individuals
has been considered to be less than 0.5μg/mL [4]. However,
in a large study carried out in two diﬀerent countries
(comprising of 2291 males and 2203 females), Hutchinson
et al. found that CRP increases as the age of individuals
increases [5]. Unfortunately, there has not been any further
study to support these data. Ever since its identiﬁcation,
CRP has found a major place in screening for the presence
of inﬂammation as well as in following the progression of
disease activity. This is mainly due to the fact that CRP
can be increased in a number of inﬂammatory processes,
for example, pneumonia, pancreatitis, pelvic inﬂammatory
disease, and urinary tract infections. Its level is also increased
in meningitis, neonatal sepsis, and occult bacteremia [6].
CRP, even though being nonspeciﬁc, has proved to be
helpful in establishing the etiology of some infections. A
high CRP value (>100mg/L) can indicate a severe bacterial
infection [7, 8]. Patients diagnosed with CAP were enrolled
inastudysoastodeterminetheroleofCRPindiﬀerentiating
CAP of diﬀerent etiologies and in treatment guidance. The
pathogens cultured from bronchoalveolar lavage (BAL) of
these patients were Streptococcus pneumonia (S. pneumonia),
viruses, Chlamydia pneumoniae, Mycoplasma pneumoniae,
Legionella pneumophila (L. pneumophila), and Coxiella bur-
netii. Serum CRP values from these patients revealed to be
valuableinthefollowingways:(1)CRPvalueswereespecially
high in patients with pneumonias caused by S. pneumoniae
orL.pneumophila;(2)CRPvaluesincreasedwiththeseverity
of disease, showing that CRP can be used to predict the
severity of disease; (3) CRP allowed the commencement
of appropriate treatment [9]. V´ azquez et al. showed that
CRP values are higher in L. pneumophila infection than
in CAP of other etiologies [10]. In 106 military conscripts
who had pneumonia, CRP, with a cut-oﬀ value of 85mg/L,
could diﬀerentiate pneumococcal pneumonia from viral and
mycoplasmal pneumonia. However, it was not useful in
distinguishing viral from mycoplasmal infection [11]. High
CRPlevelshavealsobeennoticedinpatientswithbacteremia
following pneumococcal pneumonia [12]. In subjects with
hematologic malignancies, Oﬃdani et al. found that the
level of CRP is higher in those with fungal pneumonia
thanthosewithnonfungalpneumonia[13].Indrug-induced
aspiration pneumonia, early measurement of CRP enables
the diagnosis of aerobic bacterial content [14]. According
to Smith and Lipworth, CRP can be used to diﬀerentiate
between pneumonia and acute bronchitis [15].
In children, it is even more important to establish the
etiology of pneumonia as quickly as possible as any delay
in treatment can have fatal consequences. Marcus et al.
showed that in the pediatric emergency department the
quick-read c-reactive protein test can be used to diﬀerentiate
bacterial pneumonia from viral pneumonia [16]. In a meta-
analysis of 1230 children, it was concluded that serum
CRP concentrations above 40–60mg/L are, albeit weak,
predictors of bacterial etiology [17]. Heiskanen-Kosma and
Korppi’s, on the other hand, had a quite divergent opinion.
According to them, CRP level is not associated with any
microbial etiology of pneumonia in pediatric patients. In
the study, they carried out in the Department of Pediatrics
in Kuopio University Hospital in Finland, they enrolled
193 patients with pneumococcal infection, mycoplasmal
and/or chlamydial infection and viral infections. The mean
CRP concentrations (95% conﬁdence interval) in these
groups were 26.8mg/L (20.1–33.5mg/L), 31.8mg/L (20.5–
33.1mg/L), and 26.1mg/L (19.1–33.1mg/L), respectively,
and 24.9mg/L (18.8–31.0mg/L) in patients with no etio-
logical ﬁndings [18]. A study conducted by Toikka et al.
supported these ﬁndings [19]. When it comes to Ventilator
associated pneumonia (VAP), P´ ovoa et al. showed that CRP
(>9.6mg/dL) has a good accuracy, with sensitivity of 87%
and a speciﬁcity of 88% to diagnose VAP in a population of
ICU patients. Further, high CRP levels are associated with
poor outcome [20].
Unfortunately, CRP does not allow the possibility to
distinguish between all the types of pneumonia. In a
systematicreviewpublishedinBMJin2005,itwasstatedthat
“testing for C reactive protein is neither suﬃciently sensitive
to rule out nor suﬃciently speciﬁc to rule in an inﬁltrate on
chest radiograph and bacterial etiology of lower respiratory
tract infection” [21]. However, the advantage of CRP is that
CRP levels can be used for the follow-up of pneumonia
as well as to evaluate patient management and response to
antibiotic therapy [22].
3.Procalcitonin(PCT)
Procalcitonin (PCT), a 116-amino acid peptide, is produced
by the c-cells in the thyroid and its concentration in the
serum of healthy individuals is very low (<0.1ng/mL).
During microbial infection, there is an increase of CALC-
Ig e n ee x p r e s s i o nw h i c hc a u s e sar e l e a s eo fP C Tf r o ma l l
parenchymal tissues and diﬀerentiated cell types throughout
the body, including the liver and peripheral blood mononu-
clear cells [23]. The inﬂammatory release of PCT can be
induced in two main ways: one is due to toxins released
by microbes (endotoxin); and another one is through
cell-mediated host response mediated by proinﬂammatory
cytokines (e.g., interleukins 1b and 6, tumor necrosis factor-
alpha). It should be noted that procalcitonin is also elevated
in noninfectious conditions such as trauma, surgery, car-
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syndrome, infected necrosis after acute pancreatitis, and
rejectionaftertransplantation [24–30].Today, PCTisknown
as a SMART biomarker for sepsis and infection since it
satisﬁes all the required criteria, that is, (1) it has a high
speciﬁcity and sensitivity, (2) it is readily measurable, (3) it is
aﬀordable and available in many hospitals, (4) it is responsive
and reproducible (5) having half-life of 24 hours, it can be
measured in a timely fashion [31].
The widespread use of antibiotics for nonbacterial infec-
tions has led to antibiotic resistance. In order to reduce this
phenomenon, antibiotic use must be limited to infections
of bacterial etiology [32]. This is where PCT has proved its
utility. Studies using the highly sensitive Kryptor assay have
shown that PCT guidance can lead to the safe withholding of
antibiotics among patients with low PCT levels (<0.25μg/L)
and no clinical signs of severe illness. On the other hand,
aP C T≥ 0.25 and <0.5ng/mL indicates possible bacterial
infection and it is advised to initiate antibiotic therapy in
these cases. A PCT ≥ 0.5ng/mL is suggestive of the presence
of bacterial infection and here antibiotic treatment strongly
recommended. Using the values of PCT to predict the use of
antibiotics does not only reduce the use of any unnecessary
antibiotic usage but it also decreases the duration of therapy
[31]. In 2004, Christ-Crain et al. showed that the use of PCT
reduced antibiotic overuse in patients with lower respiratory
tract infections. In their study, the risk of antibiotic exposure
was reduced by 50% [33]. In a randomized trial to determine
the length of antibiotic therapy using a laboratory parameter
was carried out in 2006, Christ-Crain et al. successfully
showed that using PCT as therapy guidance can actually
reduce the length of therapy from 12 days to 5 days and the
duration of antibiotic therapy was shortened by 65% with a
similar outcome in patients independent of the severity of
CAP [34]. A randomized, open, multicenter, noninferiority
trial carried out from December 2004 to April 2006 showed
that PCT can also be used to decrease antibiotic therapy
outside the hospital setting [35].
It has been found that the use PCT varies according
to the severity of pneumonia. In patients with a low
PneumoniaSeverityIndex(PSI,classesI-II),PCTcanpredict
microbial etiology of pneumonia. In these patients, PCT
level is higher in those with pneumonia of bacterial etiology
than in those with pneumonia of nonbacterial etiology
and hence appropriate treatment may be selected based on
measurements of PCT. On the other hand, in patients with
high PSI risk classes (classes III-V), PCT has proved to be
a good prognostic marker rather than a diagnostic marker
[36, 37]. It is well known that the diagnosis of pneumonia in
children can be very diﬃcult since the latter have nonspeciﬁc
symptoms. Moreover, it is even more important to come
to a quick diagnosis in children since delay in treatment
commencement may have fatal outcomes in these patients. A
study conducted in France in 1999 had the aim of comparing
the use of PCT in children with the use of Interleukin-6,
CRP, and Interferon-alpha for diﬀerentiating bacterial and
viral infections. The results showed that in the pediatric
emergency room, PCT is a reliable marker in the diagnosis of
bacterialCAP[38].Twoyearslater,astudycomprisingof101
children was carried out in Italy and it was found that a PCT
levelgreaterthan1.0ng/Lcanhelpindistinguishingbacterial
from viral pneumonia in children who are above 5 years of
age [39]. A study conducted by Franzin and Cabodi showed
that PCT is increased in Legionella pneumonia and, despite
its nonspeciﬁcty, it can be used as a prognostic marker [40].
These results are in concordance with that from a study
carried out by Haeuptle et al. [41].
Patients on mechanical ventilation comprise another
group of people in whom the diagnosis of pneumonia is
very challenging. In these patients, clinical ﬁndings, saliva
andtrachealspecimenculturesarenonspeciﬁcwhenitcomes
to diagnosing pneumonia. Blood cultures and pleural ﬂuid
cultures have failed to show high sensitivities. PCT, however,
has been a breakthrough in diagnosing pneumonia in this
category of patients due to its high speciﬁcity for bacterial
inﬂammation. Therefore, it is now considered a very useful
adjunct in the diagnosis of VAP of bacterial origin [42].
During the past few years, there has been growing interest
about how to predict patients who are at risk of having
VAP so as to start early antibiotic therapy. Studies have been
carried out to investigate whether PCT can be useful in this
respect. Pelosi et al. have found that in patients requiring
mechanical ventilation as a result of severe brain injury,
measurements of serum PCT level when the patients are
ﬁrst placed in ICU, along with clinical pulmonary score
infection score can be useful in predicting which patients
will subsequently have VAP [43]. Ramirez et al. came up
with the same ﬁndings and further added that CPIS and
serum PCT below the cut-oﬀ point of 2.99ng/mL are useful
in excluding false-positive diagnosis of VAP since when used
together they have a sensitivity of 100% [44]. Alveolar PCT,
on the contrary, does not help in the early diagnosis of
VAP [45]. There have been some studies which have shown
that PCT is, in fact, not a good biomarker: Linssen et al.
have found that PCT concentrations, in serum as well as in
bronchoalveolarlavageﬂuids have no value whendiagnosing
VAP [46]. The poor diagnostic capacity of PCT in VAP has
been further supported by Luyt et al. and in the same study,
they concluded that levels of PCT must not be used to guide
antibiotic therapy in patients with VAP [47].
Immunocompromised patients aresusceptibletovarious
pulmonaryinfectionsandveryoftenthesignsandsymptoms
are nonspeciﬁc. They need a quick and accurate diagnosis to
be able to start the appropriate treatment as soon as possible
and thus increase the possibility of a favorable outcome.
Stolz et al. studied BAL ﬂuid neutrophils, serum PCT, and
CRP to determine their use in the diagnosis of bacterial
pulmonary infection in immunocompromised patients. In
their study they conﬁrmed that clinical signs and symptoms
are not useful in the diﬀerential diagnosis of pulmonary
complications in these patients. However, PCT, with a cut
oﬀ value of 0.5ng/mL had a speciﬁcity of 84%; CRP, with
ac u to ﬀ v a l u eo f2 0 m g / Lh a das e n s i t i v i t yo f8 4 %a n da
speciﬁcity of 48% [48]. It is very diﬃcult to diﬀerentiate
between tuberculosis and CAP in HIV-positive patients due
to similar clinical presentations and radiographic changes.
Schleicher et al. carried out a study to determine whether
PCT and CRP levels in HIV-positive subjects can be used
to diﬀerentiate between tuberculosis and pneumonia. They4 Mediators of Inﬂammation
found that procalcitonin (level >3ng/mL) and CRP (level
>246mg/L) help in predicting pneumococcal CAP in HIV-
positive subjects [49].
Ever since PCT has started gaining widespread use,
clinicians have been questioning themselves about whether
the use of PCT has made the use of CRP obsolete. Many
studies have been conducted in order to compare the use of
PCT with that of CRP in clinical practice. PCT can be used
in the diﬀerential diagnosis of CAP from other conditions
when there is an inﬁltrate on the radiograph. M¨ uller et al.
demonstrated that PCT and hsCRP improve the diagnosis
CAP when used together [50]. In critically ill children,
PCT has been found to be a better marker of infection
as compared to CRP and leucocyte count. Moreover, a
level of PCT greater than 2ng/mL might be of use when
diﬀerentiating severe bacterial infections from non-bacterial
infections in children [51]. In a meta-analysis of 12 studies
carried out by Simon et al., it was found that even in
adults, PCT level is more sensitive (88% [95% conﬁdence
interval {CI}, 80%–93%] versus 75% [95% CI, 62%–84%])
and more speciﬁc (81% [95% CI, 67%–90%] versus 67%
[95% CI, 56%–77%]) than CRP level for diﬀerentiating
bacterial from noninfective causes of inﬂammation [52]. To
further prove the superiority of PCT over CRP, Hedlund and
Hansson carried out a study in patients being treated for
CAP.Theyfoundthat,withacut-oﬀpointof0.5ng/mL,PCT
but not CRP is able to help in the diﬀerentiation of typical
bacterial pneumonia from atypical pneumonia [53].
According to Holm et al., there is no indication that PCT
is superior to CRP in indentifying patients with pneumonia,
buttheydidmentionthatPCTmaybesuperiortoCRPwhen
distinguishing mycoplasma and other bacterial infections
[54]. PCT has been found to have a sensitivity of 100% and
speciﬁcity of 75% in indicating VAP in patients seven days
following successful cardiopulmonary resuscitation (cut oﬀ
value of 2ng/mL). The level of PCT was found to be elevated
a median of 2 days before VAP was diagnosed clinically.
Conversely, CRP has not been found to be valuable in this
respect [55].
4.Soluble TriggeringReceptor Expressedon
MyeloidCells-1(sTREM-1)
Triggering receptor expressed on myeloid cells-1 (TREM-
1) is another biomarker which holds great promise
when it comes to pneumonia. TREM-1 belongs to the
immunoglobin superfamily and is involved in inﬂammatory
response. It is expressed on the surface of neutrophils,
monocytes, and macrophages during acute inﬂammatory
responses. It has been found that the tansmembrane adapter
protein DAP12 is the signal transduction molecule through
which TREM-1 activates neutrophils and monocytes [56].
It has the advantage of being increased during infectious
processes but not in noninfectious inﬂammatory conditions
like psoriasis, ulcerative colitis, and vasculitis. TREM-1 exists
inbothamembranousandasolubleform(solubletriggering
receptor expressed on myeloid cells-1; sTREM-1) [57].
Levels of sTREM-1 have been found to be elevated in
bronchoalveolar lavage ﬂuids of patients with pneumonia,
in the plasma of septic patients, and in the exhaled breath
condensate in VAP patients [58]. However, no signiﬁcant
diﬀerence has been found in the levels obtained from CAP
and VAP patients. In a review published in Clinical Medicine
and Research, Gibot reported sTREM-1 levels ≥ 5pg/mL
weremeasuredinBALﬂuidfromapproximately95%ofCAP
patients and 100% of VAP patients as compared to 10% of
patients without pneumonia. The area under the ROC curve
to determine whether or not the patients had pneumonia
was 0.93. A cut-oﬀ value of 5pg/mL had a sensitivity of 98%
and a speciﬁcity of 90% to predict pneumonia [59]. Tejera et
al. found that serum sTREM-1 is high in patients with CAP,
and that the prognostic value of sTREM-1 is independent of
age, other inﬂammatory markers such as IL-6, Pneumonia
Severity Index, CURB-65, severity of sepsis, and nutritional
status. They also found that patients who had increased
sTREM-1 on admission had the worst prognosis [60].
In the absence of a good biomarker, all patients with
pulmonary aspiration syndrome receive antimicrobial ther-
apy when antimicrobial therapy should, in fact, be given
only to those who have infectious pneumonitis. The use of
sTREM-1todiﬀerentiatebetweenaspirationpneumoniaand
aspirationpneumonitishasbeeninvestigatedbyElSolh et al.
However, BAL ﬂuids in pulmonary aspiration syndrome
subjects with a positive culture have been found to have a
higher content of sTREM-1 (344.41 ± 152.82pg/mL) than
those who had a negative culture (142.76 ± 89.88pg/mL;
P<. 001). The cut-oﬀ value of alveolar sTREM-1 was
250pg/mL.AlveolarsTREM-1wasfoundtohaveasensitivity
of 65.8% (95% CI 48.6–80.4) and a speciﬁcity of 91.9%
(95% CI 78.1–98.2) in distinguishing between the two
conditions [61]. In a study carried out by Richeldi et al., BAL
specimens of patients with CAP, tuberculosis, and interstitial
lung diseases were collected. It was found that TREM-
1 expression is signiﬁcantly increased in lung neutrophils
and lung macrophages of patients with pneumonia caused
by extracellular bacteria as compared to patients with
pulmonarytuberculosisorinterstitial lungdiseases[62].The
presence of sTREM-1 in BAL ﬂuid may also be useful in
diagnosing bacterial or fungal pneumonia. In a study of
148 patients who were being mechanically ventilated, it was
found that sTREM-1 had a sensitivity of 98% and speciﬁcity
of 90% for the diagnosis of bacterial and fungal pneumonia
[63, 64]. This was in concordance with the study carried
out in 28 critically ill mechanically ventilated patients where
Determann et al. found that sTREM-1 has a sensitivity of
75% and speciﬁcity of 84% in diagnosing pneumonia. In
patients who developed VAP, sTREM-1 levels in BAL were
found to start rising 6 days prior to VAP diagnosis. The
greatest increase was 2 days prior to diagnosis. As for non-
VAP patients, sTREM-1 levels showed no signiﬁcant change
during the study period [65].
The use of exhaled ventilator condensate (EVC) to diag-
nose VAP is being contemplated more and more nowadays.
EVC has the advantage of being noninvasive as compared to
BAL. EVC is easily collected in the expiratory line of patients
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Horonenko et al. and they successfully demonstrated that
when clinically in doubt of VAP, sTREM-1 in EVC may be
of use in establishing the diagnosis of pneumonia [66]. It is
important to detect CAP patients who are unresponsive to
treatment at an early stage so as to be able to change the
treatment regimen. In a study conducted in Taiwan, Chao
et al. used serial changes of CRP and sTREM-1 to show
that sTREM-1 can be used in addition to CRP to detect
nonresponsive patients [67]. sTREM-1 cannot be used on
its own to diagnose pneumonia, but it can be used as a
complementary tool to reinforce the usual diagnostic work-
up. Early treatment can be started in VAP patients when
sTREM-1 is used. Furthermore, Gibot et al. stated that
combined measurement of serum PCT and BAL sTREM-1
can be useful in diﬀerentiating VAP from extrapulmonary
infection [68].
5. Other Biomarkers
A variety of other biomarkers, namely, endotoxin, proad-
renomedullin, natriuretic peptides, endothelin-1 precursor
peptides, as well as copeptin and cortisol levels, are being
studied so as to improve the diagnosis and prognosis of
pneumonia [69]. Here, it is important to point out that
biological markers are only to be used as a complementary
tool to reach diagnosis and they, in no way, replace the clin-
ical importance of diagnosis. The biomarkers are useful in
guiding culture sampling, empirical antibiotics prescription,
following clinical course of the condition and identify those
who do not respond to therapy [70]. We would also like
to point out that while Endotoxin is a diagnostic marker
just like CRP, PCT, and sTREM-1, the other biomarkers
mentioned (i.e., proadrenomedullin, natriuretic peptides,
endothelin-1 precursor peptides, as well as copeptin and
cortisol levels) have up to now only been found to be useful
as prognostic markers and may be of great help in the risk
stratiﬁcation of patients.
6.Endotoxin
Endotoxin measurements in BAL showed a relation between
its concentration and the quantity of Gram-negative bacteria
in BAL ﬂuids of VAP patients. Endotoxin allows rapid diag-
nosis of Gram-negative bacterial pneumonia [71]. Flanagan
et al. found that endotoxin level within four days of starting
mechanical ventilation is an accurate as well as a rapid way
for diagnosing VAP [72]. In a study conducted by Nys et al.,
it was established that antimicrobial Gram-negative therapy
may be justiﬁed according to the results of endotoxin level in
BAL ﬂuids of ventilated patients having pneumonia [73].
7.Copeptin andMidregionalPro-Atrial
NatriureticPeptide(MR-proANP)
First described in 1972 by Holwerda, copeptin is a 39-
amino acid glycosylated peptide with a leucine-rich core seg-
ment. Copeptin, along with antidiuretic hormone arginine
vasopressin (AVP) derive from a precursor protein, a 164-
amino acid known as pre-pro-vasopressin, which consists
of a signal peptide, AVP, neurophysin II, and copeptin [74–
77]. Copeptin is the C-terminal part of pro-AVP. Copeptin
remains stable in withdrawn blood for days and its level
c a nb em e a s u r e dq u i c k l ya n de a s i l y[ 78]. Copeptin levels in
blood have already been shown to be of use in the diagnosis
of diabetes insipidus and in the monitoring of sepsis and
cardiovascular diseases [79]. Copeptin has the advantage of
not varying with age. In a study conducted on 359 healthy
individuals, copeptin levels ranged from 1 to 13.8pmol/L,
with a median of 4.2pmol/L, and were detectable in 97.5%
of the individuals. However, it has been found that its level
is signiﬁcantly diﬀerent between the two sexes, being higher
in men than in women. In the very same study, levels of
copeptin were found to vary with exercise, fasting, and water
load [78].
M¨ uller et al. have found that copeptin levels have a
tendency to increase as the severity of lower respiratory tract
infection increases and this increase has been found to be
more pronounced in patients with CAP. Hence, copeptin
may be useful in the risk stratiﬁcation of patients with
lower respiratory tract infections [80]. When investigating
the correlation of copeptin with the severity of septic status
in patients with VAP, Seligman et al. also found that copeptin
increases progressively with severity of sepsis [81].
Atrial natriuretic peptide, primarily produced in the
cardiac atria, belongs to the natriuretic peptide family [82].
The mid-region of the prohormone of ANP, known as MR-
proANP (midregional pro-atrial natriuretic peptide) has
been found to increase with severity of sepsis and may be
used as a predictor of mortality in VAP [83]. It has been
found that MR-proANP can be used as a prognostic marker
in pneumonia [84].
The Bach study is a worldwide multicentre study with
over1600patients.ItshowsthattheuseofPCTtogetherwith
Mid-regional Pro-atrial Natriuretic Peptide (MR-proANP)
supports the diﬀerential diagnosis of pneumonia and con-
gestive heart failure [85]. B-natriuretic peptides, a well-
established biomarker belonging to the natriuretic peptide
family, may be used in the emergency department to
diﬀerentiate dyspnea of pulmonary origin from that of
cardiac origin [86].
Both MR-proANP and CT-proAVP (C-terminal pro-
vasopressin- Copeptin) can be used to predict severity of
disease in patients with CAP [87].
8. Cortisol
In early postoperative patients, posttrauma, or sepsis
patients, serum cortisol level rises. This has the beneﬁt of
redistributingeﬀectivelyenergytothevitalorgans[88].High
cortisol levels were already known to be a good prognostic
marker in sepsis. However, whether or not cortisol levels
can be used as a marker of prognosis in CAP was still
unknown. In order to investigate this, Christ-Crain et al.
conducted a study in 278 patients with CAP. They found that
initial measurements of cortisol levels (both free and total6 Mediators of Inﬂammation
cortisol) were good markers of severity and prognosis. They
were in fact as good as PSI and even better than laboratory
parameters [89].
As for proadrenomedullin and endothelin-1 precursor
peptides, they have been found to be of great use in the risk
stratiﬁcation of patients with CAP [90, 91].
9. Conclusion
The array of biomarkers available to diagnose pneumonia
and to aid its diﬀerential diagnosis from other diseases
has brought a new turn in medicine. At one time, doctors
had to rely on clinical ﬁndings and radiological ﬁndings
and thus, there was much delay in treatment initiation.
Biomarkers have improved both diagnosis and prognosis.
However, biomarkers do not make clinical ﬁndings, radio-
logical ﬁndings, and appropriate cultures obsolete. In fact,
biomarkers are to be used only as an adjunct to diagnosis
[92].
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